Efficacy and safety of adapalene 0.1 % vs. trichloroacetic acid 30% in management of molluscum contagiosum in children: A randomised controlled trial
DOI:
https://doi.org/10.66344/jpad.32.2.2022.1914Abstract
Background Molluscum contagiosum is viral infection that is quite common in children. Although many treatment options are available, but these are associated with complications of pain, erythema, scarring or recurrence.
Â
Objective Comparison of efficacy and safety of adapalene 0.1% and trichloroacetic acid 30% in management of molluscum contagiosum in children.
Â
Methods Sample size was sixty. Participants were randomized in two groups. In group A, 30 patients were treated with TCA and in group B, 30 patients were treated with adapalene. Patients were followed for 6 weeks.
Â
Results TCA was found safe in 21 (70%) patients vs. 29 (96.7%) in adapalene group (p<0.05). TCA was effective in 25 (83.3%) patients vs. 20 (66.7%) patients in adapalene group (p>0.05).
Â
Conclusion It was found that TCA is more efficacious and adapalene is safer.
Â
Key words
Adapalene, trichloroacetic acid, efficacy, safety, molluscum contagiosum.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Abdul Qayum khan, Mohammad majid paracha, Farah Sagheer, Sadia Naseem
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
